Zacks Investment Research on MSN

IDEXX (IDXX) upgraded to buy: Here's why

Idexx Laboratories (IDXX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
Ratings for IDEXX Laboratories (NASDAQ:IDXX) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview ...
While they might not represent the most exciting field in the biotech space, animal healthcare companies have been a steady, consistent source of growth in what's often a turbulent market. One company ...
IDEXX Laboratories, Inc. (IDXX)’s share price is up by 2.6% over the past month. Over the past five years, IDEXX has been up 50% in the last five years, which is less than the market return. The last ...
IDEXX Laboratories (NASDAQ:IDXX) will release its quarterly earnings report on Monday, 2026-02-02. Here's a brief overview for investors ahead of the announcement. Analysts anticipate IDEXX ...
Idexx published its third-quarter figures well before market open that day. The company divulged that its revenue was almost $1.11 billion, up a sturdy 13% from the same period of 2024. Net income ...
Is IDXX a good stock to buy? We came across a bullish thesis on IDEXX Laboratories, Inc. on X.com by @MoneyShow. In this ...
Baron Funds, an investment management company, released its “Baron Partners Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund rose modestly in the second ...
Achieves third quarter revenue growth of 7% as reported and 6% organic, supported by CAG Diagnostics recurring revenue growth of 7% as reported and organic. Organic revenue growth supported by ...
Shares of IDEXX Laboratories Inc. IDXX shed 1.43% to $570.21 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.37% to 6,556.37 ...